Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.

Trial Profile

Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Amlodipine; Atenolol; Bendroflumethiazide; Perindopril
  • Indications Cardiovascular disorders; Coronary artery disease; Essential hypertension; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ASCOT; ASCOT-10; ASCOT-BPLA; ASCOT-LLA; CAFE; CAFE-DIABETES; CARAT; EVIREST
  • Most Recent Events

    • 02 Sep 2015 Substudy results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 08 Feb 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network
    • 07 Feb 2015 Accrual to date is 96% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top